COVID-19 and organ transplant recipients, risk factors and considerations: A mini-review
1 Department of Medical Sciences, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
2 Department of Medical Sciences, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.
3 Cardiothoracic Surgery, Mayo Clinic, Jacksonville, USA.
Review
International Journal of Biological and Pharmaceutical Sciences Archive, 2022, 03(02), 136–140.
Article DOI: 10.53771/ijbpsa.2022.3.2.0066
Publication history:
Received on 07 May 2022; revised on 13 June 2022; accepted on 15 June 2022
Abstract:
The emergence of coronavirus 2 is distinctive and created an unprecedented obstacle in the entire history of organ transplantation. Transplant patients are more susceptible to COVID-19 infection due to various medical comorbidities and immunosuppressive therapy. The mortality rate was also reported as up to 30% in transplant patients. The fundamental implications of COVID-19 are different depending on the organ transplanted and the receiver's comorbidities. In addition to this, non-pharmacological interventions and vaccines help prevent COVID-19 in transplant patients. In this mini-review, we focused on summarizing current literature associated with transplant patients with COVID-19 infection, clinical outcomes, risk factors, and precautions to be taken during the pandemic.
Keywords:
Covid-19; Transplant patient; Risk Factor; Considerations
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0